In the CAPItello-291 trial of capivasertib plus fulvestrant, 73% of patients had already received a CDK4/6 inhibitor. As ...

So in summary, HER2CLIMB-05 was a positive study. It showed that adding tucatinib for both HR-positive as well as HR-negative ...

There has been an explosion of newer HER2-directed therapies, including monoclonal antibodies, novel antibody-drug conjugates ...

Verzenio monotherapy provided clinical benefits to 33% of patients with HR-positive, HER2-negative breast cancer after prior CDK4/6 inhibitor therapy. The rAMBER study highlights Verzenio's potential ...

More than one-third of U.S. adults diagnosed with metastatic HER2-negative breast cancer in 2023 did not undergo testing for BRCA mutations, according to a retrospective analysis.Less than half ...

In a Phase 1 trial, women responded well to the novel vaccine. More research is needed to determine whether it can stop the ...

ARX788 is a next-generation, site-specific antibody-drug conjugate (ADC). Its mechanism of action involves a monoclonal ...

BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious ...

RAD51-based assessment effectively identifies HER2-negative metastatic breast cancer patients likely to respond to olaparib, especially with BRCA1/2 or PALB2 variants. RAD51-low tumors showed a higher ...

The new HER2DX central nervous system (CNS) progression score predicts risk of brain progression in advanced HER2+ breast cancer, addressing a major unmet need in identifying patients at the highest ...

AT SABCS 2025, researchers presented surgical outcomes for patients who received 6 months of neoadjuvant endocrine therapy for ER-positive, HER2-negative breast cancer.

Rb1 loss may serve as a predictive biomarker to guide new targeted therapies for select breast cancers resistant to standard ...